Ablatus Therapeutics

info@ablatus.co.uk
Reveal menu
  • Home
  • Our Vision
  • People
  • Technology
    • About BETA
    • Product Development
    • Publications
  • Investors
  • News
  • Contact Us

Ablatus shortlisted for coveted #21toWatch Awards

Published on 27th June 2016 at 9:13 am.

Ablatus shortlisted for coveted #21toWatch Awards

Register for updates

Click here to ensure you receive the latest updates from Ablatus

Our Technology

Click here to learn more about BETA

  • Our technology, Bimodal Electric Tissue Ablation (BETA) is next-generation radiofrequency ablation offering larger, more effective ablations with potentially fewer adverse events and at lower cost than RFA.

Latest News

  • 8 Sep

    Mike Irvine joins Ablatus as Chief Technology Officer

    We are delighted to welcome Mike Irvine to Ablatus as our new… | Read more

  • 7 May

    Tracey Morton joins Ablatus as CFO

    We are pleased to announce the appointment of Tracey Morton who is… | Read more

  • 5 Feb

    Ablatus secures £500,000 in private finance deal

    Our recent work with Innovate UK EDGE innovation and growth specialist Emma… | Read more

  • 5 Feb

    Ablatus shortlisted for coveted #21toWatch Awards

    The 2021 shortlist for the coveted #21toWatch Awards was revealed earlier this… | Read more

  • 28 Jan

    David Lewis joins Ablatus as CEO

    We are delighted to announce the appointment of David Lewis as CEO… | Read more

Site Map

  • Home
  • Our Vision
  • People
  • Technology
    • About BETA
    • Product Development
    • Publications
  • Investors
  • News
  • Contact Us

Contact Us

Email: info@ablatus.co.uk

  • Your Privacy
  • Terms & Conditions
© 2023 Ablatus Therapeutics. All rights reserved.
Website: Pink Marketing